Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02065700 · ClinicalTrials.gov registry record · Phase 2

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

A Phase 2 study of Rheumatoid Arthritis, sponsored by Galapagos.

Completed
Registry status
Phase 2
Development phase
739
Enrollment target
20
Study locations

NCT02065700 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Galapagos. The registered enrollment target is 739 participants, below the 4,687-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02065700, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Galapagos.

COMPLETED
Registry status
Phase 2
Development phase
739 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Filgotinib

Study Locations (20)

Other

  • Atencion Integral en Reumatologa - Buenos Aires
  • CER Intituto Medico - Buenos Aires
  • Organizacion Medica de Investigaciones (OMI) - Buenos Aires
  • Instituto Reumatologico Strusberg - Córdoba
  • CIMeL Centro dee Investigacion Medico Lanus - Lanús

Florida

  • RASF Clinical Research Center - Boca Raton
  • Millenium Research - Ormond Beach
  • Lovelace Scientific Resources - Venice

Arizona

  • Arthro, Arthritis Care & Research - Gilbert
  • Arizona Arthritis & Rheumatology Research PLLC - Mesa

California

  • C.V. Mehta MD Medical Corp. - Hemet
  • Desert Medical Advances - Palm Desert

Texas

  • Austin Rheumatology Research PA - Austin
  • Pioneer Research Solutions Inc - Houston

Illinois

  • Springfield Clinic - Springfield

Maryland

  • Klein and Associates MD, PA - Hagerstown

North Carolina

  • Physicians East - Greenville

Trial Details

FieldValue
Enrollment Target 739 participants
Start Date 2014-02-25
Est. Completion 2023-01-19
Phase Phase 2

Sponsor

Galapagos

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02065700

The ClinicalTrials.gov registry entry for NCT02065700 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,687-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (84% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Filgotinib is the first listed.

NCT02065700 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02065700 about?

NCT02065700 is a clinical study titled "Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants". The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG063...

What is the current status of trial NCT02065700?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 739 participants. The study started on 2014-02-25. Estimated completion is 2023-01-19.

What conditions does trial NCT02065700 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02065700?

The interventions under investigation include: Filgotinib (DRUG).

Who is sponsoring clinical trial NCT02065700?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02065700 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.